Key Drivers
- Gross margin
- Cash conversion
- Rich valuation
AIAI Summary
LIVN has shifted from a slow medtech recovery to a credible reacceleration story driven by stronger core growth and the FDA-approved aura6000 OSA platform, but the stock now needs real commercial adoption and stronger free cash flow to justify the valuation, so investors should stay constructive only if the near-term ramp proves out.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross margin
- •Cash conversion
- •Rich valuation
Livn shows strong gross profitability and a Q1 rebound, but full-year losses, weak cash conversion in the quarter, and a rich valuation mean the turnaround must prove durable.
Price Behavior
Key Price Behavior Insights:
- •Sharp rebound
- •Resistance test
- •Support holding
Over the last month, LIVN has rebounded sharply and looks constructive above the late-April base, but it still needs to clear and hold $71.7-$72.4 to confirm further upside.
Sharp drop from 2026-04-17 to 2026-05-05, then a fast rebound into mid-May
Sentiment & News
Key News Insights:
- •Revenue Beat
- •Guidance Raise
- •Clinical Progress
LivaNova delivered a strong Q1 beat with 14% revenue growth, raised 2026 guidance, gained an analyst upgrade, and added clinical momentum from OSPREY results.
The news is likely supportive for LivaNova shares, signaling improving growth, execution, and investor sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings